Five Prime Therapeutics Inc., of South San Francisco, disclosed an expansion of its respiratory disease research collaboration with Glaxosmithkline plc, of London, that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease.